MT-3534 / Mitsubishi Tanabe - LARVOL DELTA

Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA (ACR Convergence 2025) - "The objectives of this study were to provide evidence that PAD4-related pathophysiology is the cause of non-response to existing bDMARDs and to profile the anti-arthritic effects of MT-3534 in mouse arthritis models. Human plasma PAD4 levels were measured in samples obtained from 29 RA patients treated with TNF inhibitors, IL-6 receptor inhibitors, or abatacept, and 25 healthy controls. MT-3534 inhibited arthritis in mice through a mechanism distinct. The unique mechanism of action of MT-3534 has the potential to fill an unmet medical need in the treatment of RA.AcknowledgementsMT-3534 was produced in collaboration with Pharma Foods International Co., Ltd."

Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL6

SAD Study: Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Mitsubishi Tanabe Pharma Corporation | Active, not recruiting ➔ Completed

Trial completion

PROFILING OF MT-3534, A HUMANIZED MONOCLONAL ANTIBODY TARGETING PAD4, AS A CANDIDATE DRUG FOR THE TREATMENT OF RA (EULAR 2025) - " Human plasma PAD4 levels were measured in samples obtained from 29 RA patients treated with TNF inhibitors, IL-6 receptor inhibitors, or abatacept, and 25 healthy controls...Furthermore, it was confirmed that the administration of MT-3534 to mice in which arthritis progressed despite etanercept treatment inhibited the progression of arthritis compared to mice that continued etanercept treatment alone. MT-3534 inhibited arthritis in mice through a mechanism distinct. The unique mechanism of action of MT-3534 has the potential to fill an unmet medical need in the treatment of RA."

Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL6

SAD Study: Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation | Recruiting ➔ Active, not recruiting

Enrollment closed

SAD Study: MT-3534 Clinical Pharmacology Study in Healthy Adult Male Volunteers (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation | Not yet recruiting ➔ Recruiting

Enrollment open